Zhong Guo Jing Ji Wang·2025-11-20 07:25Core Viewpoint - Shuoshi Bio (688399.SH) reported a decline in revenue and net profit for the first three quarters of 2025, indicating financial challenges faced by the company [1]. Financial Performance - The company achieved operating revenue of 258 million yuan, a year-on-year decrease of 3.95% [1][3]. - The net profit attributable to shareholders was 3.15 million yuan, down 88.38% compared to the previous year [1][3]. - The net profit after deducting non-recurring gains and losses was -41.39 million yuan [1][3]. - The net cash flow from operating activities was 19.42 million yuan, a significant decline of 79.90% year-on-year [1][3]. Previous Year Comparison - In 2024, Shuoshi Bio reported operating revenue of 350 million yuan, a decrease of 13.29% compared to the previous year [4]. - The net profit attributable to shareholders for 2024 was -2 million yuan, an improvement from -37.38 million yuan in the previous year [4]. - The net profit after deducting non-recurring gains and losses was -7.18 million yuan, also an improvement from -42.92 million yuan in the previous year [4]. - The net cash flow from operating activities for 2024 was 145.93 million yuan, showing a significant increase of 228.97% year-on-year [4]. Stock Issuance and Financial Activities - Shuoshi Bio raised a total of 685.79 million yuan from its initial public offering, with a net amount of 612.93 million yuan, exceeding the original plan by 210.28 million yuan [5]. - The company planned to use the raised funds for the Taizhou headquarters industrial park project [5]. - The total issuance costs for the IPO were 72.86 million yuan, including underwriting fees of 54.93 million yuan [5].